Indivior's SUBLOCADE: A Leap Forward in Opioid Treatment
Indivior's Recent FDA Announcement
RICHMOND, Va. - Indivior PLC (NASDAQ:LSE: INDV), a dedicated pharmaceutical company, has exciting news to share with the healthcare community and patients battling opioid use disorder (OUD). The U.S. Food and Drug Administration (FDA) has granted Priority Review for a Prior Approval Supplement (PAS) concerning SUBLOCADE (buprenorphine extended-release) injection. This development aims to broaden the usage of SUBLOCADE by including alternative injection sites and introducing a rapid induction protocol that could significantly meet the urgent needs of patients and healthcare providers.
Updated Administration Methods for SUBLOCADE
The proposed changes in the drug labeling allow for subcutaneous administration not just in the abdomen but also in the thigh, buttock, and the upper arm's back. Furthermore, this new protocol could potentially shorten the induction period from the traditional seven days down to just one hour, following a single dose of transmucosal buprenorphine. This expedited induction could enable the administration of a second dose as early as one week after the initial shot, catering to patient-specific needs.
Evidence Supporting the New Protocol
Indivior's submission to the FDA is backed by thorough data, showcasing the safety and effectiveness of SUBLOCADE when employed with this new rapid induction method and the proposed alternative injection sites. The Priority Review status indicates that the FDA aims to finalize its review within six months—much quicker than the usual ten-month timeline.
The Role of SUBLOCADE in Treating OUD
Currently, SUBLOCADE is indicated for treating moderate to severe opioid use disorder in patients who have begun treatment with a buprenorphine-containing product, followed by dose adjustments for at least a week. Importantly, it is not intended for use alone; comprehensive treatment programs including counseling and psychosocial support are essential for optimal outcomes.
Safety and Common Side Effects
As with any medication, SUBLOCADE comes with its risks. It carries a boxed warning regarding the serious potential risks associated with intravenous administration. Patients can only access this medication through a restricted program known as the SUBLOCADE REMS Program due to these dangers. Common side effects reported include constipation, headache, nausea, injection site itching, vomiting, increased hepatic enzymes, fatigue, and injection site pain.
Implications of FDA's Decision Timeline
The FDA's final verdict regarding the PAS is anticipated in early February. An approval for these label expansions could represent a transformative step in how OUD is treated with SUBLOCADE, potentially leading to a broader range of patients benefiting from this therapy.
Recent Developments for Indivior PLC
In addition to the recent FDA news, Indivior PLC has been navigating various developments. Craig-Hallum recently revised its stock price target for Indivior from $24.00 to $20.00 but retained a Buy rating, reflective of ongoing reassessment of the company's financial outlook. Conversely, Piper Sandler has maintained an Overweight rating, highlighting the exciting potential for SUBLOCADE in addressing opioid addiction.
Securing Additional Orders
Indivior also recently registered an impressive $8.7 million order from the Biomedical Advanced Research and Development Authority (BARDA) for OPVEE®, a medication planned for opioid overdose reversal. This order is poised to enhance emergency response capabilities at a crucial time marked by the ongoing opioid crisis.
Investing and Financial Insights
As Indivior awaits the FDA's decision regarding the label expansion for SUBLOCADE, investors may benefit from understanding the company's recent financial metrics and market performance. As of now, Indivior's market capitalization sits at approximately $1.33 billion, which underscores its significant role in the pharmaceutical sector.
Growth and Projections
The company's revenue showcased an impressive growth rate of 14.47% over the past twelve months, with a recent quarterly growth of 8.33%. This positive trend aligns well with potential market expansion awaiting the FDA's approval for the updates concerning injection sites and the rapid induction process. Analysts anticipate that Indivior's net income will grow this year, with expectations of profitability underpinned by the hopeful labeling changes for SUBLOCADE that could boost sales.
Frequently Asked Questions
What is SUBLOCADE used for?
SUBLOCADE is used for treating moderate to severe opioid use disorder in patients who have been stabilized on a buprenorphine-containing product.
What changes are being proposed for SUBLOCADE's usage?
The proposed updates allow SUBLOCADE to be administered at various sites, including the thigh and upper arm, with a rapid induction protocol.
How does the FDA prioritize its reviews?
The FDA's Priority Review status expedites the review process, aiming for a completion within six months instead of the usual ten months.
What are the common side effects of SUBLOCADE?
Typical side effects include constipation, headache, nausea, tiredness, and injection site pain or itching.
What is the significance of the BARDA order for Indivior?
The $8.7 million order from BARDA for OPVEE® supports emergency response efforts and highlights Indivior's role in combating the opioid crisis.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- AMMO, Inc. Class Action Update: Important Deadline Approaches
- North Carolina Companies Unite for Hurricane Relief Efforts
- Pfizer's Stock Movement: Impact of Starboard Value's Stake
- Interactive Brokers Sets New Record in Election Forecast Trading
- Outset Medical, Inc. Investors: Important Class Action Update
- The Surge of In-Vitro Diagnostics: Market Overview and Trends
- Constellation Brands Faces Challenges as Wine Sales Decline
- Jason Cromer Steps into Leadership Role at LandSouth Construction
- Vantiva and Harmonic Forge a New Path in Fiber Technology Advancements
- Trends in Wholesale Used Vehicle Prices as of September 2024
Recent Articles
- Transforming Healthcare: JOSH AI Redefines Clinical Documentation
- Belden Inc. Achieves Historic Stock Surge with Positive Outlook
- Pita Pit Partners with Killer Brownie® to Enhance Offerings
- TechTarget Faces Market Challenges as Stock Hits Low at $23.05
- Exploring Deer Park's New Fund for Commercial Investments
- Cummins Inc Reaches All-Time High with Robust Q2 Performance
- RELM Wireless Achieves New Heights with Significant Gains
- Polish Stock Market Shows Positive Trends with Key Sectors Up
- Unilever's Major Supply Chain Revamp Aiming for Growth
- Fnac Darty Lowers Threshold for Unieuro Acquisition Offer
- Wood Coatings Market Set for Remarkable Growth to $30.1 Billion
- Revolutionary DeFi Innovation Launches on the Avalanche Network
- HTC VIVE and Virtualware Join Forces to Enhance XR Adoption
- Voting Rights and Share Capital Overview for FORVIA
- Voltalia SA Shares and Voting Rights Update for Investors
- Euronext Reports Impressive Trading Volumes for September
- Overview of Rexel's Share Structure and Voting Rights
- Gran Tierra Energy's Strategic Takeover of i3 Energy Gains Approval
- Invitation to EssilorLuxottica's Q3 2024 Revenue Call Opportunity
- Innovative Bond Issuance by RCI Banque Marks Key Financial Milestone
- Aramis Group Announces Share Buybacks for Early October 2024
- Galecto Inc (GLTO) Faces Stock Decline Amid Strategic Shift
- Syensqo's Strategic Share Buyback: A Step Forward
- Insights on CleanSpark's Stock Performance Amid Bitcoin Surge
- Klépierre Reveals Total Voting Rights and Share Updates
- Ferrellgas Celebrates National Propane Day with Community Support
- Moe Rock's Strategic Acquisition: Enhancing Local Reporting
- WisdomTree's Groundbreaking Amendments to VIX Securities
- Mytheresa's New Acquisition: A Step Towards Luxury Expansion
- Malta Explores Safe Cannabis Consumption and New Regulations
- Rising Oil Prices Amidst Tensions in the Middle East Region
- Stephen M. Scherr Takes the Helm at Pretium as Co-President
- Exploring the Booming Growth of France's Gift Card Market
- Essential Estate Planning Tips for Everyone to Follow
- Exploring Cybersecurity Trends in the Financial Sector Market
- Investing $100 in American Tower: A 20-Year Growth Story
- Transform Your Investment: LII Stock Surges Over 10 Years
- Earnings Anticipation of Curaleaf and MariMed: A Deeper Look
- Explore the Chic New KitchenAid Refrigerator: Style Meets Function
- Growing Demand for Aluminium Screw Caps Boosts Market Value
- Clean View Auto Wash Joins Forces with Jax Kar Wash for Growth
- Revolutionizing Legal Practice with Clio Duo's AI Innovations
- Experience the Rhythm: Dominica's World Creole Music Festival
- Blazesoft Unveils Yay Casino: A New Era in Online Gaming
- Exploring Clio's Findings on AI's Rapid Adoption in Law Firms
- Gran Tierra Energy's Strategic Acquisition of i3 Energy: Insights
- Gyrodyne's Annual Meeting: Insights and Future Directions
- Danish Stocks Surge as OMX Copenhagen 20 Gains Over 2%
- Turkey Stock Market Analysis: BIST 100 Experiences Decline
- Exploring the Rise of Meta Platforms in Communication Stocks